For the launch of ZYNLONTA, the creative brief … evolved. First try: The decision to pursue CR is clear. Second take: Get a rapid CR. Once more with feeling: CR in a broad range of patients.
One of the pivotal considerations in the treatment of DLBCL is whether a patient is chemosensitive, which helps determine if they are eligible to receive a stem cell transplant. This was not a factor with ZYNLONTA. Just about any 3L patient could be a candidate for ZYNLONTA, including those who have received another CD19-directed therapy.
